{"id":"m701","safety":{"commonSideEffects":[]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"M701 functions as a bispecific antibody designed to target multiple immune regulatory pathways simultaneously, thereby overcoming tumor immune evasion mechanisms. By engaging dual checkpoints, the drug aims to synergistically enhance T cell activation and proliferation against cancer cells. This approach is intended to improve therapeutic efficacy compared to single-checkpoint inhibitors.","oneSentence":"M701 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:49:38.633Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced solid tumors (Phase 3 development)"}]},"trialDetails":[{"nctId":"NCT06432296","phase":"PHASE3","title":"Treatment of Malignant Ascites Caused by Advanced Epithelial Solid Tumors With M701 Bispecific Antibody","status":"ACTIVE_NOT_RECRUITING","sponsor":"Wuhan YZY Biopharma Co., Ltd.","startDate":"2024-03-20","conditions":"Malignant Ascites","enrollment":312},{"nctId":"NCT05543330","phase":"PHASE1, PHASE2","title":"A Phase Ib/II Clinical Trial of M701 in the Treatment of Malignant Pleural Effusions Caused by NSCLC","status":"RECRUITING","sponsor":"Wuhan YZY Biopharma Co., Ltd.","startDate":"2022-09-30","conditions":"Malignant Pleural Effusions, NSCLC Stage IV","enrollment":96},{"nctId":"NCT06266091","phase":"PHASE2","title":"Treat Malignant Ascites Caused by Gastrointestinal or Ovarian Cancer With M701 Bispecific Antibody","status":"COMPLETED","sponsor":"Wuhan YZY Biopharma Co., Ltd.","startDate":"2021-11-24","conditions":"Malignant Ascites","enrollment":115},{"nctId":"NCT04501744","phase":"PHASE1","title":"A Study of M701 (EpCAM and CD3) in Malignant Ascites","status":"COMPLETED","sponsor":"Wuhan YZY Biopharma Co., Ltd.","startDate":"2018-09-30","conditions":"Malignant Ascites, Cancer","enrollment":35}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":9,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"M701","genericName":"M701","companyName":"Wuhan YZY Biopharma Co., Ltd.","companyId":"wuhan-yzy-biopharma-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"M701 is a bispecific antibody that simultaneously engages two distinct immune checkpoints to enhance anti-tumor T cell responses. Used for Advanced solid tumors (Phase 3 development).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":false,"trials":true,"score":3}}